

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
Any case, cluster of cases, outbreak, or exposure to an infectious or non-infectious disease, condition, or agent found in the general community or any defined setting such as a hospital, school or other institution, not listed in this rule that is of urgent public health significance. This includes human cases, clusters, or outbreaks spread person-to-person, by animals or vectors or from an environmental, food or	X	X				X	X			

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
waterborne source of exposure; those that result from a deliberate act of terrorism; and unexplained deaths possibly due to unidentified infectious or chemical causes.										
Acquired Immune Deficiency Syndrome (AIDS)				2 weeks	Laboratory Reporting Not Applicable					
Amebic Encephalitis	X								X	

Practitioner Reporting				Laboratory Reporting								
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes							
	Suspect Immediately	Immediately	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediately	Next Business Day	Other		
Arsenic Poisoning *4a			X	Laboratory results as specified in the surveillance case definition *4a					X			
Arboviral infections, not otherwise listed in this table (disease due to) *5	X			Including but not limited to: Flaviviridae, Togaviridae (e.g. chikungunya, Western equine encephalitis), Bunyaviridae (e.g. Heartland, Rift Valley Fever) *5	X	X						
Babesiosis			X	Babesia spp.	X				X			
Botulism, foodborne, other (includes wound and unspecified)	X	X		<i>Clostridium botulinum</i> or botulinum toxin	X	X	X					

Practitioner Reporting				Laboratory Reporting								
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes							
	Suspect Immediately	Immediately	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediately	Next Business Day	Other		
Botulism, infant				<i>Clostridium botulinum</i> or botulinum toxin	X					X		
Brucellosis	X	X		<i>Brucella</i> species	X	X	X					
California serogroup viruses-(disease due to)				California serogroup viruses such as Jamestown Canyon, Keystone, and Lacrosse	X						X	
Campylobacteriosis *4b				<i>Campylobacter</i> species *4b					X			

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
Cancer (except non-melanoma skin cancer, and including benign and borderline intracranial and CNS tumors) *6			6 months	Pathological or tissue diagnosis of cancer (except non-melanoma skin cancer and including benign and borderline intracranial and CNS tumors)				6 months		
Carbon monoxide poisoning		X		A volume fraction \geq 0.09 (9%) of carboxyhemoglobin in blood			X			
CD-4 absolute count and percentage of total lymphocytes	Practitioner Reporting Not Applicable			CD-4 absolute count and percentage of total lymphocytes *7				3 days		
Chancroid		X		<i>Haemophilus ducreyi</i>			X			
Chlamydia *8		X		<i>Chlamydia trachomatis</i>			X			

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
Cholera	X	X		<i>Vibrio cholerae</i>	X	X	X			
Ciguatera fish poisoning			X	Ciguatera fish poisoning	Laboratory Reporting Not Applicable					
Congenital anomalies *9			6 months	Congenital anomalies	Laboratory tests as specified in Rule 64D-3.035, F.A.C.					
Conjunctivitis in neonates < 14 days old			X	Conjunctivitis in neonates < 14 days old	Laboratory Reporting Not Applicable					
Coronavirus (COVID-19) *23		X		Coronavirus (COVID-19) *23			X			
Creutzfeld-Jakob disease (CJD) *10			X	14-3-3 or tau protein detection in CSF or immunohistochemical test or any brain pathology suggestive of CJD *10				X		
Cryptosporidiosis *4b			X	<i>Cryptosporidium</i> species *4b				X		

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
Cyclosporiasis			X		X			X		
Dengue *5	X				X	X				
Diphtheria	X	X			X	X	X			
Eastern equine encephalitis			X		X			X		
Ehrlichiosis/Anaplasmosis			X		X			X		
<i>Escherichia coli</i> Shiga toxin-producing (disease due to) *4b			X		X			X		
Giardiasis (acute) *4b			X					X		
Glanders	X	X			X	X	X			
Gonorrhea *8			X					X		

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
Granuloma inguinale			X						X	
<i>Haemophilus influenzae</i> , meningitis and invasive disease, in children < 5 years old	X	X			X	X	X	X		
Hansen disease (Leprosy)			X						X	
Hantavirus infection	X				X		X			
Hemolytic uremic syndrome	X				Not Applicable					
Hepatitis A *4b, 12	X							X		
Hepatitis B, C, D, E and G *12			X						X	

Practitioner Reporting				Laboratory Reporting							
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes						
	Suspect Immediately	Next Business Day	Other		Submit isolates or specimens for confirmation *1	Suspect Immediately	Next Business Day	Immediately	Other		
Hepatitis B surface antigen (HBsAg)-positive in a pregnant woman or a child up to 24 months old		X		Hepatitis B surface antigen (HBsAg)				X			
Herpes B virus, possible exposure		X		Herpes B virus, possible exposure	Laboratory Reporting Not Applicable						
Herpes simplex virus (HSV) in infants up to 60 days old with disseminated infection with involvement of liver, encephalitis and infections limited to skin, eyes and mouth *13			X	HSV 1 or HSV 2 by direct FA, PCR, DNA or Culture *13				X			
HSV – anogenital in children < 12 years of age *8, 13			X	HSV 1 or HSV 2 by direct FA, PCR, DNA or Culture *13				X			

Practitioner Reporting				Laboratory Reporting							
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes						
	Suspect Immediately	Next Business Day	Other		Submit isolates or specimens for confirmation *1	Suspect Immediately	Next Business Day	Immediately	Other		
Human immunodeficiency virus (HIV) infection			2 weeks	Repeatedly reactive enzyme immunoassay, followed by a positive confirmatory tests, (e.g. Western Blot, IFA): Positive result on any HIV virologic test (e.g. p24 AG, Nucleic Acid Test (NAT/NAAT) or viral culture). All viral load (detectable and undetectable) test results.*14, 15							3 days

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
Human immunodeficiency virus (HIV) Exposed Newborn – infant < 18 months of age born to a HIV infected woman			X							3 days
Human papillomavirus (HPV) associated laryngeal papillomas or recurrent respiratory papillomatosis in children < 6 years of age *8			X						X	
Human papillomavirus (HPV) – anogenital papillomas in children < 12 years of age *8			X						X	

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
Human papillomavirus (HPV)				Practitioner Reporting Not Applicable						X
Influenza due to novel or pandemic strains	X	X								X
Influenza-associated pediatric mortality in persons aged < 18 years				X					X	
Influenza				Practitioner Reporting Not Applicable						X

Practitioner Reporting				Laboratory Reporting							
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes						
	Suspect Immediately	Immediately	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediately	Next Business Day	Other	
Lead poisoning *4, 16			X	All blood lead test results (positive and negative) *3, 4, 16				X			
Legionellosis			X	<i>Legionella</i> species				X			
Leptospirosis			X	<i>Leptospira</i> species				X			
Listeriosis		X		<i>Listeria monocytogenes</i>	X		X				
Lyme disease			X	<i>Borrelia burgdorferi</i>				X			
Lymphogranuloma Venereum (LGV)			X	<i>Chlamydia trachomatis</i>				X			
Malaria			X	<i>Plasmodium</i> species	X			X			
Measles (Rubeola)	X	X		Measles virus *16	X	X	X				
Melioidosis	X	X		<i>Burkholderia pseudomallei</i>	X	X	X				

Practitioner Reporting				Laboratory Reporting							
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes						
	Suspect Immediately	Immediately	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediately	Next Business Day	Other	
Meningitis, bacterial or mycotic				X	Isolation or demonstration of any bacterial or fungal species in cerebrospinal fluid				X		
Meningococcal disease	X	X			<i>Neisseria meningitidis</i>	X		X			
Mercury poisoning *4a				X	Laboratory results as specified in the surveillance case definition *4a				X		
Mumps				X	Mumps virus				X		
Neonatal Abstinence Syndrome *18				6 months	Neonatal Abstinence Syndrome	Laboratory Reporting Not Applicable					

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediately	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediately	Next Business Day	Other
Neurotoxic shellfish poisoning		X						X		
Pertussis		X		<i>Bordetella pertussis</i>				X		
Pesticide-related illness and injury *4			X	Laboratory results as specified in the surveillance case definition *4					X	
Plague	X	X		<i>Yersinia pestis</i>	X	X	X			
Poliomyelitis	X	X		Poliovirus	X	X	X			
Psittacosis (Ornithosis)			X	<i>Chlamydia psittaci</i>	X				X	
Q Fever			X	<i>Coxiella burnetii</i>	X				X	
Rabies, animal or human		X		Rabies virus		X	X			
Rabies, possible exposure *19	X	X		Rabies, possible exposure	Laboratory Reporting Not Applicable					

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediately	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediately	Next Business Day	Other
Respiratory syncytial virus				Practitioner Reporting Not Applicable						X
Ricin toxicity	X	X		Ricinine (from <i>Ricinus communis</i> castor beans)	X	X	X			
Rocky Mountain spotted fever and other Spotted Fever Rickettsioses				<i>Rickettsia rickettsii</i> and other Spotted Fever <i>Rickettsia</i> species	X					X
Rubella, including congenital	X	X		Rubella virus *17	X	X	X			
St. Louis encephalitis (SLE)			X	St. Louis encephalitis virus	X					X
Salmonellosis *4b			X	<i>Salmonella</i> species *4b	X					X

Practitioner Reporting				Laboratory Reporting							
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes						
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other	
Saxitoxin poisoning including Paralytic shellfish poisoning (PSP)			X						X		
Severe acute respiratory disease syndrome-associated with a Coronavirus infection	X	X			X	X	X				
Shigellosis *4b			X						X		
Smallpox	X	X			X	X	X				
<i>Staphylococcus aureus</i> isolated from a normally sterile site	Practitioner Reporting Not Applicable									X	

Practitioner Reporting				Laboratory Reporting							
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes						
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other	
<i>Staphylococcus aureus</i> with intermediate or full resistance to vancomycin (VISA, VRSA); Laboratory results as specified in the surveillance case definition *4			X						X	X	
Staphylococcus enterotoxin B			X						X	X	
<i>Streptococcus pneumoniae</i> , invasive disease in children < 6 years, drug sensitive and resistant							X				X
Syphilis			X								X

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
Syphilis in pregnant women and neonates	X						X			
Tetanus		X						X		
Trichinellosis (Trichinosis)		X						X		
Tuberculosis (TB) *21			X		X			X		
Tularemia	X	X			X	X	X			
Typhoid fever and paratyphoid fever *4b		X			X			X		
Typhus fever (epidemic)	X	X			X	X	X			
Vaccinia disease	X	X			X	X	X			

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediate	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediate	Next Business Day	Other
Varicella (Chickenpox) *22			X						X	
Varicella mortality			X						X	
Venezuelan equine encephalitis	X	X			X	X	X			
Vibriosis (infections by <i>Vibrio</i> species and closely related organisms, other than Cholera)							X		X	

Practitioner Reporting				Laboratory Reporting						
Reportable Diseases or Conditions	Timeframes			Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results)	Timeframes					
	Suspect Immediately	Immediately	Next Business Day		Other	Submit isolates or specimens for confirmation *1	Suspect Immediately	Immediately	Next Business Day	Other
Viral hemorrhagic fevers	X	X			X	X	X			
West Nile virus (disease due to)			X		X			X		
Yellow fever	X	X			X		X			
Zika fever *5	X				X	X				

*1 through *22 No change.

*23– Special reporting requirements for COVID-19:

a. All PCR and antigen test results (positive, negative, and inconclusive results), including screening test results, must be immediately reported, and accompanied by the type of test performed (e.g. PCR and antigen).

b. Point-of-Care Test Reporting Requirements – Practitioners, laboratories, facilities, and all others using point-of-care tests for the diagnosis of COVID-19, including those operating under CLIA waivers, must report both the negative and positive test results to the Department within 24 hours of test administration.

c. In addition to the data element fields required by Rules 64D-3.030 and 64D-3.031, all test results reported must include the CLIA number of the reporting practitioner, laboratory, or facility.

d. All test results must be submitted electronically, using one of the electronic reporting methods listed below. Registration in one of these methods, must be completed within 7 days of obtaining the ability to conduct testing. Until electronic laboratory reporting has been established, positive test results must be submitted by facsimile to the Florida Department of Health’s Bureau of Epidemiology confidential fax line, (850)414-6894, or to the patient’s local county health department. List of county health department reporting contact information can be found at www.FLhealth.gov/chdepcontact. For enrollment into electronic laboratory reporting or the direct entry web portal, visit www.FloridaHealth.gov/ElectronicReportingRegistration.

1. Electronic laboratory reporting for reporting entities that can generate an electronic comma-separated value (CSV) or Health Level 7 (HL7) formatted message.

2. Web portal for entities that perform COVID-19 testing and are unable to generate an electronic CSV or HL7 formatted message. Such entities may include long-term care facilities, assisted living facilities, nursing homes, rehabilitation centers, schools, colleges, universities, or other congregate care settings.

3. National Healthcare Safety Network (NHSN) COVID-19 module for CMS-certified long-term care facilities. Test data submitted to NHSN will be reported to appropriate state and local health departments using standard electronic laboratory messages.

Rulemaking Authority 381.0011(2), 381.003(2), 381.0031(8), 384.33, 392.53(2), 392.66 FS. Law Implemented 381.0011(3), (4), 381.003(1), 381.0031(2), (4), (5), (6), (8), 383.06, 384.25, 385.202, 392.53 FS. History–New 11-20-06, Amended 11-24-08, 6-4-14, 10-20-16, _____.

NAME OF PERSON ORIGINATING PROPOSED RULE:
Carina Blackmore

NAME OF AGENCY HEAD WHO APPROVED THE PROPOSED RULE: Scott A. Rivkees, MD, Surgeon General and Secretary

DATE PROPOSED RULE APPROVED BY AGENCY HEAD: June 22, 2021

DATE NOTICE OF PROPOSED RULE DEVELOPMENT PUBLISHED IN FAR: June 1, 2020

Section III Notice of Changes, Corrections and Withdrawals

NONE

Section IV
Emergency Rules

NONE

Section V
Petitions and Dispositions Regarding Rule
Variance or Waiver

DEPARTMENT OF LAW ENFORCEMENT
Criminal Justice Standards and Training Commission

RULE NO.: RULE TITLE:

11B-27.002 Certification, Employment or Appointment, Reactivation, and Terminating Employment or Appointment of Officers

NOTICE IS HEREBY GIVEN that on June 16, 2021, the Department of Law Enforcement, received a petition for permanent waiver of subsection 11B-27.002(4) by Myrna Ayala Simmons. Petitioner wishes to waive that portion of the rule that states: (a) Within four years of the beginning date of a Commission-approved Basic Recruit Training Program, an individual shall successfully complete the program, achieve a passing score on the applicable State Officer Certification Examination, and gain employment, and certification as an officer.

A copy of the Petition for Variance or Waiver may be obtained by contacting: Agency Clerk, Florida Department of Law Enforcement, P.O. Box 1489 Tallahassee, FL, 32302 or by telephone at (850)410-7676.

DEPARTMENT OF LAW ENFORCEMENT
Criminal Justice Standards and Training Commission

RULE NO.: RULE TITLE:

11B-27.00213 Temporary Employment Authorization

NOTICE IS HEREBY GIVEN that on June 22, 2021, the Department of Law Enforcement, received a petition for permanent waiver of Rule 11B-27.00213, F.A.C. by Terrance Maurice Gadson. Petitioner wishes to waive that portion of the rule that states: (4) Agencies applying to temporarily employ or appoint an individual who has had a previous TEA registered with the Commission in the same discipline, may do so only if: (a) The individual was previously certified as a full-time or part-time officer; or

(b) The individual was previously hired on a TEA and has separated from the employing agency or discontinued training while still in good standing, and has had a break-in-service from the last employment for a minimum of four years.

A copy of the Petition for Variance or Waiver may be obtained by contacting: Agency Clerk, Florida Department of Law

Enforcement, P.O. Box 1489 Tallahassee, FL, 32302 or by telephone at (850)410-7676.

DEPARTMENT OF BUSINESS AND PROFESSIONAL REGULATION

Division of Hotels and Restaurants

RULE NO.: RULE TITLE:

61C-4.010 Sanitation and Safety Requirements

NOTICE IS HEREBY GIVEN that on June 29, 2021, the Florida Department of Business and Professional Regulation, Division of Hotels and Restaurants, received a petition for A Routine Variance for paragraph 3-305.11(A)(2), 2017 FDA Food Code, Section 3-305.14, 2017 FDA Food Code, Section 6-202.15, 2017 FDA Food Code, Section 6-202.16, 2017 FDA Food Code, subsection 61C-4.010(1), Florida Administrative Code, and subsection 61C-4.010(6), Florida Administrative Code from Bobby's Catering located in Hiialeah. The above referenced F.A.C. addresses the requirement for proper handling and dispensing of food. They are requesting to dispense bulk time/temperature control for safety foods from an open air mobile food dispensing vehicle.

The Division of Hotels and Restaurants will accept comments concerning the Petition for 14 days from the date of publication of this notice. To be considered, comments must be received before 5:00 p.m.

A copy of the Petition for Variance or Waiver may be obtained by contacting: Kasimira.Kelly@myfloridalicense.com, Division of Hotels and Restaurants, 2601 Blair Stone Road, Tallahassee, Florida 32399-1011.

DEPARTMENT OF HEALTH

Board of Optometry

RULE NO.: RULE TITLE:

64B13-4.001 Examination Requirements

NOTICE IS HEREBY GIVEN that on June 28, 2021, the Board of Optometry, received a petition for variance or waiver filed by Raazia Syedda. Petitioner is seeking a variance or waiver of subparagraphs 64B13-4.001(1)(d)2. and 3., F.A.C., which states in part that the licensure examination authorized in subsection 463.006(2), F.S., shall consist of four parts with one being the Florida Practical Examination. The Florida Practical Examination shall consist of three (3) tested skills and the Board requires passage of all three (3) skills on the same test attempt. The three (3) skills are Biomicroscopy, Binocular Indirect Ophthalmoscopy, Dilated Biomicroscopy and Non-Contact Fundus Lens Evaluation and are weighted equally. The passing score for each skill shall be seventy-five percent (75%) or better, and a passing score on each of the three (3) skills must be obtained on the same test attempt.

A copy of the Petition for Variance or Waiver may be obtained by contacting: Christina McGinnis, Executive Director, Board of Optometry, 4052 Bald Cypress Way, Bin #C07, Tallahassee,

FL 32399-3257. Christina.McGinnis@myfloridahealth.gov. Comments on this petition should be filed with the Board of Optometry within 14 days of publication of this notice.

DEPARTMENT OF HEALTH

Board of Optometry

RULE NO.: RULE TITLE:

64B13-4.001 Examination Requirements

NOTICE IS HEREBY GIVEN that on June 28, 2021, the Board of Optometry, received a petition for variance or waiver filed by Tina Thomas. Petitioner is seeking a variance or waiver of subparagraphs 64B13-4.001(1)(d)2. and 3., F.A.C., which states in part that the licensure examination authorized in subsection 463.006(2), F.S., shall consist of four parts with one being the Florida Practical Examination. The Florida Practical Examination shall consist of three (3) tested skills and the Board requires passage of all three (3) skills on the same test attempt. The three (3) skills are Biomicroscopy, Binocular Indirect Ophthalmoscopy, Dilated Biomicroscopy and Non-Contact Fundus Lens Evaluation and are weighted equally. The passing score for each skill shall be seventy-five percent (75%) or better, and a passing score on each of the three (3) skills must be obtained on the same test attempt.

A copy of the Petition for Variance or Waiver may be obtained by contacting: Christina McGinnis, Executive Director, Board of Optometry, 4052 Bald Cypress Way, Bin #C07, Tallahassee, FL 32399-3257. Christina.McGinnis@myfloridahealth.gov. Comments on this petition should be filed with the Board of Optometry within 14 days of publication of this notice.

DEPARTMENT OF HEALTH

Board of Optometry

RULE NO.: RULE TITLE:

64B13-4.001 Examination Requirements

NOTICE IS HEREBY GIVEN that on June 28, 2021, the Board of Optometry, received a petition for variance or waiver filed by Alexia S. Clark. Petitioner is seeking a variance or waiver of subparagraph 64B13-4.001(1)(d)2. and 3., F.A.C., which states in part that the licensure examination authorized in subsection 463.006(2), F.S., shall consist of four parts with one being the Florida Practical Examination. The Florida Practical Examination shall consist of three (3) tested skills and the Board requires passage of all three (3) skills on the same test attempt. The three (3) skills are Biomicroscopy, Binocular Indirect Ophthalmoscopy, Dilated Biomicroscopy and Non-Contact Fundus Lens Evaluation and are weighted equally. The passing score for each skill shall be seventy-five percent (75%) or better, and a passing score on each of the three (3) skills must be obtained on the same test attempt.

A copy of the Petition for Variance or Waiver may be obtained by contacting: Christina McGinnis, Executive Director, Board of Optometry, 4052 Bald Cypress Way, Bin #C07, Tallahassee,

FL 32399-3257. Christina.McGinnis@myfloridahealth.gov. Comments on this petition should be filed with the Board of Optometry within 14 days of publication of this notice.

FLORIDA HOUSING FINANCE CORPORATION

RULE NO.: RULE TITLE:

67-48.0072 Credit Underwriting and Loan Procedures

NOTICE IS HEREBY GIVEN that on June 29, 2021, the Florida Housing Finance Corporation, received a petition for waiver of paragraph 67-48.0072(28)(g) (7/11/2019) Florida Administrative Code from Cedar Oaks Senior Housing Limited Partnership to allow the Seller Note and Sponsor Note to be combined for purposes of determining the minimum qualifying first mortgage test utilized in the gap calculation.

A copy of the Petition for Variance or Waiver may be obtained by contacting: Ana McGlamory, Corporation Clerk, Florida Housing Finance Corporation, 227 North Bronough Street, Suite 5000, Tallahassee, FL 32301-1329. The Petition has also been posted on Florida Housing's website at floridahousing.org. Florida Housing will accept comments concerning the Petition for 14 days from the date of publication of this notice. To be considered, comments must be received on or before 5:00 p.m., Eastern Time, on the 14th day after publication of this notice at Florida Housing Finance Corporation, 227 North Bronough Street, Suite 5000, Tallahassee, Florida 32301-1329.

FLORIDA HOUSING FINANCE CORPORATION

RULE NO.: RULE TITLE:

67-48.0072 Credit Underwriting and Loan Procedures

NOTICE IS HEREBY GIVEN that on June 29, 2021, the Florida Housing Finance Corporation, received a petition for waiver of paragraph 67-48.0072(28)(g) (7/11/2019) Florida Administrative Code from Palm Harbor Senior Housing Limited Partnership to allow the Seller Note and Sponsor Note to be combined for purposes of determining the minimum qualifying first mortgage test utilized in the gap calculation.

A copy of the Petition for Variance or Waiver may be obtained by contacting: Ana McGlamory, Corporation Clerk, Florida Housing Finance Corporation, 227 North Bronough Street, Suite 5000, Tallahassee, FL 32301-1329. The Petition has also been posted on Florida Housing's website at floridahousing.org. Florida Housing will accept comments concerning the Petition for 14 days from the date of publication of this notice. To be considered, comments must be received on or before 5:00 p.m., Eastern Time, on the 14th day after publication of this notice at Florida Housing Finance Corporation, 227 North Bronough Street, Suite 5000, Tallahassee, Florida 32301-1329.

FISH AND WILDLIFE CONSERVATION COMMISSION
 Freshwater Fish and Wildlife
 RULE NO.: RULE TITLE:
 68A-6.010 Facility Requirements for Class I, II and III
 Wildlife
 NOTICE IS HEREBY GIVEN that on June 23, 2021, the Florida Fish and Wildlife Conservation Commission, received a petition for a waiver from subparagraph 68A-6.010(3)(b)2., Florida Administrative Code, which sets out the land area requirement for facilities housing Class II wildlife. The petition was submitted by Gena Walck of Heaven Help Us Animal Refuge. Comments regarding the petition will be accepted for 14 days from the date of publication of this notice.
 A copy of the Petition for Variance or Waiver may be obtained by contacting: Capt. Kara Hooker, Florida Fish and Wildlife Conservation Commission, Captive Wildlife Program, 620 South Meridian Street, Tallahassee, FL 32399-1600 or by calling (850)488-6253.

Section VI Notice of Meetings, Workshops and Public Hearings

DEPARTMENT OF AGRICULTURE AND CONSUMER SERVICES
 The Jackson Soil and Water Conservation District announces a public meeting to which all persons are invited.
 DATE AND TIME: July 7, 2021, 9:00 a.m. CT
 PLACE: Jackson County IFAS Extension Office, Bull Pen, 2741 Penn. Avenue, Marianna, FL 32448
 GENERAL SUBJECT MATTER TO BE CONSIDERED: Current and Upcoming Grant Programs.
 A copy of the agenda may be obtained by contacting: Lola Allard, (850)372-4793 office.
 Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 1 days before the workshop/meeting by contacting: If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).
 For more information, you may contact: Lola Allard, (850)372-4793 office.

DEPARTMENT OF AGRICULTURE AND CONSUMER SERVICES
 Division of Plant Industry
 RULE NO.: RULE TITLE:
 5B-57.007 Noxious Weed List
 The DIVISION OF PLANT INDUSTRY announces a public meeting to which all persons are invited.
 DATE AND TIME: July 21, 2021, 10:00 a.m. – 12:00 Noon.
 PLACE: Please join this Teams meeting from your computer, tablet or smartphone. https://teams.microsoft.com/l/meetup-join/19%3ameeting_MDEzMGZiMWEtMzRkOC00ZjA4LTk5NjEtMGQxMTNmNWQ5N2Jj%40thread.v2/0?context=%7b%22Tid%22%3a%2262557d98-bd11-4a88-8a7b-57bc3df0190b%22%2c%22Oid%22%3a%2239bf1703-e19f-4647-a705-6a48b3aca9c3%22%7d
 GENERAL SUBJECT MATTER TO BE CONSIDERED: Aligning the Florida state noxious weed list with the USDA federal noxious weed list; Considering for nomination: Cinnamomum camphora (camphor tree) and Pyrus calleryana (callery pear)
 A copy of the agenda may be obtained by contacting: Dr. Patti Anderson at (352)395-4701 or Patti.Anderson@fdacs.gov.

DEPARTMENT OF BUSINESS AND PROFESSIONAL REGULATION
 Board of Architecture and Interior Design
 The Board of Architecture and Interior Design announces a public meeting to which all persons are invited.
 DATE AND TIME: July 13, 2021, 9:00 a.m.
 PLACE: Hilton Orlando- Bonnet Creek, 14100 Bonnet Creek Resort Lane, Orlando, FL 32821.
 GENERAL SUBJECT MATTER TO BE CONSIDERED: Jose Albez 2021-003386; Rodolfo Alfonso 2021-013922; Architectural Support Services, Inc. 2019-040211; Ian Faber 2019-040218; Debbie Faber 2019-040228; ARK Architects 2021-003153; J. Ramon Bancalero 2021-003396; Design Pros 2021-005029; Barry Webb; Brent Ducker 2021-013921; Aldo Gomez 2020-042012; Christopher Haywood 2021-004969; Integrated Design Studio 2020-048898; Henry Schein; Sergio Jimenez 2021-003405; Diego Suarez Jurado 2021-003222; Sean Kessler 2021-010587; Nikita Kirillin 2021-003402; Andres Lopez 2021-004568; Manuel Moriche 2021-003216; Santiago Ruiz Moriche 2021-003226; Guadalupe Parada 2021-003235; Ricardo Zafra-Polo 2021-003230
 A copy of the agenda may be obtained by contacting: David K. Minacci, Manausa, Shaw & Minacci, PA, 140-D W. 1st Street, St. George Island, FL 32328, (850)799-1882.
 Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 5 days before the workshop/meeting by

contacting: David K. Minacci, Manausa, Shaw & Minacci, PA, 140-D W. 1st Street, St. George Island, FL 32328, (850)799-1882. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

For more information, you may contact: David K. Minacci, Manausa, Shaw & Minacci, PA, 140-D W. 1st Street, St. George Island, FL 32328, (850)799-1882.

DEPARTMENT OF HEALTH

Board of Nursing Home Administrators

The Department of Health announces a public meeting to which all persons are invited.

DATE AND TIME: July 29, 2021, 9:00 a.m.

PLACE: Rosen Shingle Creek, 9939 Universal Boulevard, Orlando, Florida 32819

GENERAL SUBJECT MATTER TO BE CONSIDERED: ISSUE 47/116 - This meeting has been canceled.

A copy of the agenda may be obtained by contacting: <https://floridasnursinghomeadmin.gov>.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 7 days before the workshop/meeting by contacting: If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

For more information, you may contact: Christina.McGinnis@flhealth.gov.

DEPARTMENT OF HEALTH

Board of Nursing Home Administrators

The Department of Health announces a telephone conference call to which all persons are invited.

DATE AND TIME: July 29, 2021, 9:00 a.m.

PLACE: <https://global.gotomeeting.com/join/850969461>

GENERAL SUBJECT MATTER TO BE CONSIDERED: General board business to include licensure.

A copy of the agenda may be obtained by contacting: <https://floridasnursinghomeadmin.gov>.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 7 days before the workshop/meeting by contacting: If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

For more information, you may contact: Christina.McGinnis@flhealth.gov.

DEPARTMENT OF HEALTH

Division of Children's Medical Services

The Florida Department of Health/ Division of Children's Medical Services/ Early Steps Program announces a public meeting to which all persons are invited.

DATE AND TIME: July 12, 2021, 9:00 a.m. – 10:00 a.m. ET

PLACE: https://teams.microsoft.com/l/meetup-join/19%3ameeting_YzQ1YTljZGYtMDgxNi00ODhhLWIxMTEtZTUyNDJhZWJIMzIz%40thread.v2/0?context=%7b%22Tid%22%3a%2228cd8f80-3c44-4b27-81a0-cd2b03a31b8d%22%2c%22Oid%22%3a%22533018a0-f734-4b13-921a-d78abc916779%22%7d

GENERAL SUBJECT MATTER TO BE CONSIDERED: The Early Steps Child and Family Outcomes Stakeholder Group, Professional Development/Learning Community Subgroup is conducting a meeting to assist and advise the Early Steps Program.

A copy of the agenda may be obtained by contacting: Lily.Wells@flhealth.gov.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 3 days before the workshop/meeting by contacting: Lily.Wells@flhealth.gov. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

For more information, you may contact: Lily.Wells@flhealth.gov.

ORANGE COUNTY RESEARCH AND DEVELOPMENT AUTHORITY

The Orange County Research and Development Authority announces a public meeting to which all persons are invited.

DATE AND TIME: July 15, 2021, 10:30 a.m.

PLACE: Central Florida Research Park, 12424 Research Parkway, Suite 100, Orlando, FL 32826

GENERAL SUBJECT MATTER TO BE CONSIDERED: General Business Meeting

A copy of the agenda may be obtained by contacting: Joe Wallace, (407)282-3944.

WALTON COUNTY HEALTH DEPARTMENT

The Walton County Health Department announces a public meeting to which all persons are invited.

DATE AND TIME: Thursday, July 15, 2021, 11:30 a.m.

PLACE: Walton County Health Department

GENERAL SUBJECT MATTER TO BE CONSIDERED: Various Board Information

A copy of the agenda may be obtained by contacting: Tabatha Walters, (850)892-8015, ext 6237.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 7 days before the workshop/meeting by contacting: Tabatha Walters, (850)892-8015, ext 6237. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

For more information, you may contact: Tabatha Walters, (850)892-8015, ext 6237.

Section VII

Notice of Petitions and Dispositions Regarding Declaratory Statements

DEPARTMENT OF FINANCIAL SERVICES

FSC - Financial Institution Regulation

NOTICE IS HEREBY GIVEN that the Florida Office of Financial Regulation has issued an order disposing of the petition for declaratory statement filed by Banco de Credito e Inversiones. on June 7, 2021. The following is a summary of the agency's disposition of the petition: On June 28, 2021, a Final Order on the Petition was issued. The petition sought a declaratory statement from the Office accepting Bank of New York Mellon, which does not have a full branch in the State of

Florida, to serve as the custodian for an investment portfolio to comply with Capital Equivalency requirement pursuant to Section 663.07, Florida Statutes and OFR-U-29 form. The Office determined that the Petitioner is authorized under Section 633.07, Florida Statutes, to utilize the Bank of New York Mellon to hold its capital equivalency deposits and may enter into the Capital Equivalency Deposit Agreement, Form OFR-U-29, with the Bank of New York Mellon as the depository bank. *****The original petition was published June 7, 2021 in the Florida Administrative Register Volume 47, Number 109.

A copy of the Order Disposing of the Petition for Declaratory Statement may be obtained by contacting: Agency Clerk, Office of Financial Regulation, P.O. Box 8050, Tallahassee, Florida 32314-8050, (850)410-9889, Agency.Clerk@flofr.gov.

Please refer all comments to: Agency Clerk, Office of Financial Regulation, P.O. Box 8050, Tallahassee, Florida 32314-8050, (850)410-9889, Agency.Clerk@flofr.gov.

DEPARTMENT OF FINANCIAL SERVICES

Finance

NOTICE IS HEREBY GIVEN that the Florida Office of Financial Regulation has received the petition for declaratory statement from Virtu Financial Global Markets LLC. The petition seeks the agency's opinion as to the applicability of Chapter 560, Florida Statutes, as it applies to the petitioner.

The Florida Office of Financial Regulation (Consumer Finance) received a Petition for Declaratory Statement from petitioner seeking whether its business model (to operate an over-the-counter (“OTC”) digital asset trading desk to trade cryptocurrencies with direct institutional counterparties) requires licensure under the Florida Money Transmitter Statute, Chapter 560, Florida Statutes.

A copy of the Petition for Declaratory Statement may be obtained by contacting: Agency Clerk, Office of Financial Regulation, P.O. Box 8050, Tallahassee, Florida 32314-8050, (850)410-9889, Agency.Clerk@flofr.gov.

Please refer all comments to: Agency Clerk, Office of Financial Regulation, P.O. Box 8050, Tallahassee, Florida 32314-8050, (850)410-9889, Agency.Clerk@flofr.gov.

Section VIII

Notice of Petitions and Dispositions Regarding the Validity of Rules

Notice of Petition for Administrative Determination has been filed with the Division of Administrative Hearings on the following rules:

NONE

Notice of Disposition of Petition for Administrative Determination has been filed with the Division of Administrative Hearings on the following rules:

NONE

Section IX

Notice of Petitions and Dispositions Regarding Non-rule Policy Challenges

NONE

Section X

Announcements and Objection Reports of the Joint Administrative Procedures Committee

NONE

Section XI

Notices Regarding Bids, Proposals and Purchasing

DEPARTMENT OF JUVENILE JUSTICE

“ITN 10714 – Public Meetings”

ITN 10174- The Department is seeking a forty (40) bed Residential Program for girls appropriate for non-secure or secure residential placement, who are between the ages of twelve (12) and nineteen (19). The program shall include innovations in delinquency programming and treatment services.

All public meetings for this RFP are advertised on the Vendor Bid System at: https://www.myflorida.com/apps/vbs/vbs_www.ad_r2.view_ad?advertisement_key_num=159545.

DEPARTMENT OF FINANCIAL SERVICES

2122-02 ITN RM Pharmacy Benefit Management Services

The Department of Financial Services (Department) is issuing this Invitation to Negotiate (ITN) to solicit Responses from one or more entities (Respondents) that are qualified and capable of providing Pharmacy Benefit Management Services. The solicitation will be administered through the Vendor Bid System (VBS). The submitted Response must comply with the terms and conditions stated in the ITN.

Point of Contact/Procurement Officer: All questions must be in writing and should reference the above solicitation number and title. Submit all questions to Procurement Officer, Laura Jennings, via email at DFSPurchasing@myfloridacfo.com.

Response Due Date: 8/13/2021 by 3:00 p.m. ET, to the Procurement Officer identified, at the following office location: Department of Financial Services, 200 East Gaines Street, Larson Building, Suite 146, Tallahassee, Florida 32399-0347.

The Department reserves the right to issue amendments, addenda, and changes to the timeline and specifically to any public meeting identified within the solicitation. The Department will post notice of any changes regarding this solicitation or additional meetings within the VBS in accordance with subsection 287.042(3), Florida Statutes, and will not re-advertise the notice in the Florida Administrative Register (FAR). To access the VBS go to the following web address: http://vbs.dms.state.fl.us/vbs/main_menu.

ADA Requirements: Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in any meeting is asked to advise the agency at least 48 hours before the meeting by contacting: Procurement Officer – see above. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

CITY OF BONITA SPRINGS

NOTICE OF RECEIPT OF UNSOLICITED PROPOSALS AND INVITATION TO SUBMIT PROPOSALS TO DESIGN AND CONSTRUCT RECREATIONAL AND CIVIC FACILITIES ON CITY-OWNED LAND UNDER A COMMERCIAL AND RESIDENTIAL LAND LEASE

PLEASE TAKE NOTICE that the City of Bonita Springs, Florida, has received unsolicited proposals from private entities pursuant to Section 255.065, Florida Statutes, to design and construct recreational and civic facilities in conjunction with a commercial and residential land lease on approximately 5.3± acres of City-owned lands located in the plat of “Bonita Springs” according to the plat thereof recorded in Plat Book 3, Page 26 of the Public Records of Lee County, Florida, including Lots J and K and that part of Lot I South of Leffert Creek and North of the Imperial River and all of Blocks 6 and 7, and Lots 4, 5, 6, 7, and 8 of Block 5, together with the East ½ of the alley vacated by the Lee County Commission, Minutes Book 51, page 442, and the West ½ of the alley vacated by the Lee County Commission, Minutes Book 51, page 442, said lands situate, lying and being in the City of Bonita Springs, Lee County, Florida, commonly known as Imperial Crossing. The City of Bonita Springs will accept other proposals for the same project. Other proposals must be received in writing and in accordance with Section 255.065, Florida Statutes, to the City of Bonita Springs Attn: City Clerk, 9101 Bonita Beach Road, Bonita Springs, Florida, 34135, before 5:00 p.m. Eastern Time on Wednesday, July 14, 2021. For more information, contact Derek Rooney, City Attorney, at derek.rooney@gray-robinson.com.

**Section XII
Miscellaneous**

DEPARTMENT OF STATE

Index of Administrative Rules Filed with the Secretary of State Pursuant to subparagraph 120.55(1)(b)6. – 7., F.S., the below list of rules were filed in the Office of the Secretary of State between 3:00 p.m., Wednesday, June 23, 2021 and 3:00 p.m., Tuesday, June 29, 2021.

Rule No.	File Date	Effective Date
6A-1.0014	6/24/2021	7/14/2021
6A-1.0018	6/24/2021	7/14/2021
6A-1.0943	6/24/2021	7/14/2021
6A-1.09963	6/24/2021	7/14/2021
6A-1.09981	6/24/2021	7/14/2021
6A-4.002	6/24/2021	7/14/2021
6A-6.03311	6/24/2021	7/14/2021
6A-6.0571	6/24/2021	7/14/2021
6A-6.0573	6/24/2021	7/14/2021
6A-6.0575	6/24/2021	7/14/2021
6A-10.0401	6/24/2021	7/14/2021
6A-14.0582	6/24/2021	7/14/2021
6B-10.009	6/23/2021	7/13/2021
6B-10.012	6/23/2021	7/13/2021
6N-1.005	6/24/2021	7/14/2021
12AER21-2	6/24/2021	6/24/2021
42QQ-1.002	6/23/2021	7/13/2021
61G18-30.005	6/25/2021	7/15/2021
61-35.029	6/23/2021	7/13/2021
64B1-4.001	6/28/2021	7/18/2021
64B4-2.002	6/25/2021	7/15/2021
64B7-26.003	6/28/2021	7/18/2021
64B8-3.002	6/25/2021	7/15/2021
64B8-3.003	6/25/2021	7/15/2021

64B8-4.009	6/23/2021	7/13/2021
64B4-55.002	6/28/2021	7/18/2021
64B8-9.018	6/23/2021	7/13/2021
64B8-9.0181	6/23/2021	7/13/2021
64B8-31.012	6/25/2021	7/15/2021
64B9-15.002	6/25/2021	7/15/2021
64B9-15.0025	6/25/2021	7/15/2021
64B9-15.0026	6/25/2021	7/15/2021
64B15-7.012	6/25/2021	7/15/2021
64B15-14.013	6/23/2021	7/13/2021
64B15-14.0131	6/23/2021	7/13/2021

LIST OF RULES AWAITING LEGISLATIVE APPROVAL SECTIONS 120.541(3), 373.139(7) AND/OR 373.1391(6), FLORIDA STATUTES

Rule No.	File Date	Effective Date
60FF1-5.009	7/21/2016	**/**/****
60P-1.003	11/5/2019	**/**/****
60P-2.002	11/5/2019	**/**/****
60P-2.003	11/5/2019	**/**/****
64B8-10.003	12/9/2015	**/**/****

DEPARTMENT OF HIGHWAY SAFETY AND MOTOR VEHICLES

Division of Motor Vehicles

Establishment of Briggs Equipment, Inc., line-make KALM

Notice of Publication for a New Point

Franchise Motor Vehicle Dealer in a County of More than 300,000 Population

Pursuant to Section 320.642, Florida Statutes, notice is given that Kalmar USA, Inc., intends to allow the establishment of Briggs Equipment, Inc., as a dealership for the sale of automobiles manufactured by Kalmar Industries Corp.; Kalmar Solutions LLC (line-make KALM) at 2230 North US Highway 301, Tampa, (Hillsborough County), Florida 33619, on or after July 30, 2021.

The name and address of the dealer operator(s) and principal investor(s) of Briggs Equipment, Inc are dealer operator(s): Eric Sweat, 2230 North US Highway 301, Tampa, Florida 33619;

principal investor(s): Sammons Enterprises, Inc, 5949 Sherry Lane, Dallas, Texas 75225.

The notice indicates intent to establish the new point location in a county of more than 300,000 population, according to the latest population estimates of the University of Florida, Bureau of Economic and Business Research.

Certain dealerships of the same line-make may have standing, pursuant to Section 320.642, Florida Statutes, to file a petition or complaint protesting the application.

Written petitions or complaints must be received by the Department of Highway Safety and Motor Vehicles within 30 days of the date of publication of this notice and must be submitted to: Jaime Williams, Administrator, Dealer License Section, Department of Highway Safety and Motor Vehicles, Room A-312 MS65, Neil Kirkman Building, 2900 Apalachee Parkway, Tallahassee, Florida 32399-0635.

A copy of such petition or complaint must also be sent by US Mail to: Mindy Hutton, Kalmar USA, Inc., 415 East Dundee Street, Ottawa, Kansas 66067.

If no petitions or complaints are received within 30 days of the date of publication, a final order will be issued by the Department of Highway Safety and Motor Vehicles approving the establishment of the dealership, subject to the applicant's compliance with the provisions of Chapter 320, Florida Statutes.

DEPARTMENT OF HIGHWAY SAFETY AND MOTOR VEHICLES

Division of Motor Vehicles

Establishment of SRQ Scooters LLC, line-make NGBO

Notice of Publication for a New Point

Franchise Motor Vehicle Dealer in a County of More than 300,000 Population

Pursuant to Section 320.642, Florida Statutes, notice is given that Genuine Scooters LLC, intends to allow the establishment of SRQ Scooters LLC, as a dealership for the sale of motorcycles manufactured by Ningbo Longjia Motorcycle Co. Ltd. (line-make NGBO) at 4715 Swift Road, Unit 3, Sarasota, (Sarasota County), Florida 34231, on or after July 30, 2021.

The name and address of the dealer operator(s) and principal investor(s) of SRQ Scooters LLC are dealer operator(s): Walt Ottaviano, 4715 Swift Road, Unit 3, Sarasota, Florida 34231; principal investor(s): Walt Ottaviano, 4715 Swift Road, Unit 3, Sarasota, Florida 34231.

The notice indicates intent to establish the new point location in a county of more than 300,000 population, according to the latest population estimates of the University of Florida, Bureau of Economic and Business Research.

Certain dealerships of the same line-make may have standing, pursuant to Section 320.642, Florida Statutes, to file a petition or complaint protesting the application.

Written petitions or complaints must be received by the Department of Highway Safety and Motor Vehicles within 30 days of the date of publication of this notice and must be submitted to: Jaime Williams, Administrator, Dealer License Section, Department of Highway Safety and Motor Vehicles, Room A-312 MS65, Neil Kirkman Building, 2900 Apalachee Parkway, Tallahassee, Florida 32399-0635.

A copy of such petition or complaint must also be sent by US Mail to: Sarah Miyashiro, Genuine Scooters LLC, 2700 West Grand Avenue, Chicago, Illinois 60612.

If no petitions or complaints are received within 30 days of the date of publication, a final order will be issued by the Department of Highway Safety and Motor Vehicles approving the establishment of the dealership, subject to the applicant's compliance with the provisions of Chapter 320, Florida Statutes.

DEPARTMENT OF HIGHWAY SAFETY AND MOTOR VEHICLES

Division of Motor Vehicles

Establishment of SRQ Scooters LLC, line-make JDRA

Notice of Publication for a New Point

Franchise Motor Vehicle Dealer in a County of More than 300,000 Population

Pursuant to Section 320.642, Florida Statutes, notice is given that Genuine Scooters LLC, intends to allow the establishment of SRQ Scooters LLC, as a dealership for the sale of motorcycles manufactured by Royal Alloy By Jiangsu Dafier Motorcycle Co., Ltd (line-make JDRA) at 4715 Swift Road, Unit 3, Sarasota, (Sarasota County), Florida 34231, on or after July 30, 2021.

The name and address of the dealer operator(s) and principal investor(s) of SRQ Scooters LLC are dealer operator(s): Walt Ottaviano, 4715 Swift Road, Unit 3, Sarasota, Florida 34231; principal investor(s): Walt Ottaviano, 4715 Swift Road, Unit 3, Sarasota, Florida 34231.

The notice indicates intent to establish the new point location in a county of more than 300,000 population, according to the latest population estimates of the University of Florida, Bureau of Economic and Business Research.

Certain dealerships of the same line-make may have standing, pursuant to Section 320.642, Florida Statutes, to file a petition or complaint protesting the application.

Written petitions or complaints must be received by the Department of Highway Safety and Motor Vehicles within 30 days of the date of publication of this notice and must be submitted to: Jaime Williams, Administrator, Dealer License Section, Department of Highway Safety and Motor Vehicles, Room A-312 MS65, Neil Kirkman Building, 2900 Apalachee Parkway, Tallahassee, Florida 32399-0635.

A copy of such petition or complaint must also be sent by US Mail to: Sarah Miyashiro, Genuine Scooters LLC, 2700 West Grand Avenue, Chicago, Illinois 60612.

If no petitions or complaints are received within 30 days of the date of publication, a final order will be issued by the Department of Highway Safety and Motor Vehicles approving the establishment of the dealership, subject to the applicant's compliance with the provisions of Chapter 320, Florida Statutes.

DEPARTMENT OF HIGHWAY SAFETY AND MOTOR VEHICLES

Division of Motor Vehicles

Establishment of SRQ Scooters LLC, line-make M0TV

Notice of Publication for a New Point

Franchise Motor Vehicle Dealer in a County of More than 300,000 Population

Pursuant to Section 320.642, Florida Statutes, notice is given that Genuine Scooters LLC, intends to allow the establishment of SRQ Scooters LLC, as a dealership for the sale of motorcycles manufactured by Motive Power Industry Co., Ltd (line-make M0TV) at 4715 Swift Road, Unit 3, Sarasota, (Sarasota County), Florida 34231, on or after July 30, 2021.

The name and address of the dealer operator(s) and principal investor(s) of SRQ Scooters LLC are dealer operator(s): Walt Ottaviano, 4715 Swift Road, Unit 3, Sarasota, Florida 34231; principal investor(s): Walt Ottaviano, 4715 Swift Road, Unit 3, Sarasota, Florida 34231.

The notice indicates intent to establish the new point location in a county of more than 300,000 population, according to the latest population estimates of the University of Florida, Bureau of Economic and Business Research.

Certain dealerships of the same line-make may have standing, pursuant to Section 320.642, Florida Statutes, to file a petition or complaint protesting the application.

Written petitions or complaints must be received by the Department of Highway Safety and Motor Vehicles within 30 days of the date of publication of this notice and must be submitted to: Jaime Williams, Administrator, Dealer License Section, Department of Highway Safety and Motor Vehicles, Room A-312 MS65, Neil Kirkman Building, 2900 Apalachee Parkway, Tallahassee, Florida 32399-0635.

A copy of such petition or complaint must also be sent by US Mail to: Sarah Miyashiro, Genuine Scooters LLC, 2700 West Grand Avenue, Chicago, Illinois 60612.

If no petitions or complaints are received within 30 days of the date of publication, a final order will be issued by the Department of Highway Safety and Motor Vehicles approving the establishment of the dealership, subject to the applicant's compliance with the provisions of Chapter 320, Florida Statutes.

AGENCY FOR HEALTH CARE ADMINISTRATION

Medicaid

State Plan Amendment

The Agency for Health Care Administration announces that it is requesting an amendment to the Medicaid State Plan. The amendment updates Diagnosis Related Group (DRG) reimbursement rates for hospital inpatient services as authorized in the General Appropriations Act for State Fiscal Year 2021-2022, and makes technical and editorial changes. This amendment to the State Plan will have no federal fiscal impact federal fiscal year (FFY) 2020-21 and for FFY 2021-22. The effective date for this amendment will be July 1, 2021.

Interested parties may contact the following staff for further information:

Tanisha Feehrer, Medicaid Program Finance, located at 2727 Mahan Drive, Mail Stop 23, Tallahassee, Florida 32308-5407, by telephone at: (850)412-4095 or by e-mail at: tanisha.feehrer@ahca.myflorida.com.

AGENCY FOR HEALTH CARE ADMINISTRATION

Medicaid

State Plan Amendment

The Agency for Health Care Administration is requesting an amendment to the Medicaid State Plan. The amendment updates Enhanced Ambulatory Patient Group (EAPG) reimbursement rates for hospital outpatient services as authorized in the General Appropriations Act for State Fiscal Year 2021-2022 and makes technical and editorial changes. This amendment to the State Plan will have no federal fiscal impact for federal fiscal year (FFY) 2020-21 and for FFY 2021-22. The effective date for this amendment will be July 1, 2021.

Interested parties may contact the following staff for further information:

Tanisha Feehrer, Medicaid Program Finance, located at 2727 Mahan Drive, Mail Stop 23, Tallahassee, Florida 32308-5407, by telephone at: (850)412-4095 or by e-mail at: tanisha.feehrer@ahca.myflorida.com.

AGENCY FOR HEALTH CARE ADMINISTRATION

Medicaid

State Plan Amendment

The Agency for Health Care Administration is requesting an amendment to the Medicaid State Plan. The amendment updates buy-back provisions for Intermediate Care Facilities for Individuals with Developmental Disabilities and establishes a new level of reimbursement for Medicaid eligible individuals residing in or seeking admission to an Intermediate Care Facilities for Individuals with Developmental Disabilities who have severe behavioral needs as authorized in the General Appropriations Act for State Fiscal Year 2021-2022, and makes technical and editorial changes. This amendment to the State Plan will have a federal fiscal impact with an expected increase

of \$2,427,628 in federal funds for federal fiscal year (FFY) 2020-21 and an increase of \$7,282,885 in federal funds for FFY 2021-22. The effective date for this amendment will be July 1, 2021.

Interested parties may contact the following staff for further information:

Rydell Samuel, Medicaid Program Finance, located at 2727 Mahan Drive, Mail Stop 23, Tallahassee, Florida 32308-5407, by telephone at: (850)412-4103 or by e-mail at: rydell.samuel@ahca.myflorida.com.

AGENCY FOR HEALTH CARE ADMINISTRATION

Medicaid

State Plan Amendment

The Agency for Health Care Administration is requesting an amendment to the Medicaid State Plan for the County Health Department Reimbursement Plan. The amendment updates buy-back provisions as authorized in the General Appropriations Act for State Fiscal Year 2021-2022, and makes technical and editorial changes. This amendment to the State Plan will have a federal fiscal impact with an expected increase of \$131,919 in federal funds for federal fiscal year (FFY) 2020-21 and an increase of \$395,756 in federal funds for FFY 2021-22. The effective date for this amendment will be July 1, 2021.

Interested parties may contact the following staff for further information: Rydell Samuel, Medicaid Program Finance, located at 2727 Mahan Drive, Mail Stop 23, Tallahassee, Florida 32308-5407, by telephone at: (850)412-4103 or by e-mail at: rydell.samuel@ahca.myflorida.com.

AGENCY FOR HEALTH CARE ADMINISTRATION

Medicaid

State Plan Amendment

The Agency for Health Care Administration is requesting an amendment to the Medicaid State Plan for the Long-Term Care Reimbursement Plan. The amendment updates provisions as authorized in the General Appropriation’s Act for State Fiscal Year 2021-2022 and makes technical and editorial changes. This amendment to the State Plan will have a federal fiscal impact with an expected increase of \$3,407,198 for federal fiscal year (FFY) 2020-21 and an expected increase of \$10,221,593 for FFY 2021-22. The effective date for this amendment will be July 1, 2021.

Interested parties may contact the following staff for further information: Zainab Day, Medicaid Program Finance, located at 2727 Mahan Drive, Mail Stop 23, Tallahassee, Florida 32308-5407, by telephone at: (850)412-4798 or by e-mail at: Zainab.Day@AHCA.MyFlorida.com.

AGENCY FOR HEALTH CARE ADMINISTRATION

Medicaid

State Plan Amendment

The Agency for Health Care Administration is requesting an amendment to the Medicaid State Plan for the Long-Term Care Reimbursement Plan. The amendment updates provisions as authorized in the General Appropriation’s Act for State Fiscal Year 2021-2022 and makes technical and editorial changes. This amendment to the State Plan will have a federal fiscal impact with an expected increase of \$3,407,198 for federal fiscal year (FFY) 2020-21 and an expected increase of \$10,221,593 for FFY 2021-22. The effective date for this amendment will be July 1, 2021.

Interested parties may contact the following staff for further information: Zainab Day, Medicaid Program Finance, located at 2727 Mahan Drive, Mail Stop 23, Tallahassee, Florida 32308-5407, by telephone at: (850)412-4798 or by e-mail at: Zainab.Day@AHCA.MyFlorida.com.

AGENCY FOR HEALTH CARE ADMINISTRATION

Medicaid

State Plan Amendment

The Agency for Health Care Administration is requesting an amendment to the Medicaid State Plan. The amendment seeks approval to update the State Plan to end previously approved emergency provisions related to the COVID-19 Public Health Emergency. This amendment to the State Plan will have no federal fiscal impact for federal fiscal year (FFY) 2020-21 and a decrease of \$8,126,638 in federal funds for FFY 2021-22. The effective date for this amendment will be July 1, 2021.

Interested parties may contact the following staff for further information: Cole Giering, Bureau of Medicaid Policy, located at 2727 Mahan Drive, Mail Stop 20, Tallahassee, Florida 32308-5407, by telephone at: (850)412-4691 or by e-mail at: Cole.Giering@ahca.myflorida.com.

DEPARTMENT OF ENVIRONMENTAL PROTECTION

Clean Water State Revolving Fund

NOTICE OF AVAILABILITY

FLORIDA FINDING OF NO SIGNIFICANT IMPACT

City of Blountstown, Florida

The Florida Department of Environmental Protection (DEP) has determined that the City of Blountstown’s project to rehabilitate the wastewater treatment plant and construct an alternate disposal system is not expected to generate controversy over potential environmental effects. The total estimated construction cost is \$6,263,250. The project may qualify for a Clean Water State Revolving Fund (CWSRF) loan comprised of federal or state funds. DEP will consider public comments about the environmental impacts of the proposed project that are postmarked or delivered at the address below within 30 days of this notice. A full copy of the FLORIDA

FINDING OF NO SIGNIFICANT IMPACT (FFONSI) can be obtained by writing to: Michael Chase, CWSRF Program, Department of Environmental Protection, 3900 Commonwealth Boulevard, MS#3505, Tallahassee, Florida 32399-3000 or calling (850)245-2913 or emailing to Michael.Chase@FloridaDEP.gov.

DEPARTMENT OF ENVIRONMENTAL PROTECTION
Office of the Secretary
Florida State Clearinghouse

The state is coordinating reviews of federal activities and federally funded projects as required by subsection 403.061(42), F.S. This includes Outer Continental Shelf activities and other actions subject to federal consistency review under the Florida Coastal Management Program. A list of projects, comments and deadlines, and the address for providing comments, are available at: <https://fldep.dep.state.fl.us/clearinghouse/>. For information, call (850)717-9076. This public notice fulfills the requirements of 15 CFR 930.

DEPARTMENT OF CHILDREN AND FAMILIES
Substance Abuse Program

Fiscal Year 2020/2021 Methadone Needs Assessment
RULE NO.: RULE TITLE:

65D-30.0141 Needs Assessment for Medication-Assisted Treatment for Opioid Use Disorders.

In accordance with Rule 65D-30.0141, F.A.C., the Department has published the results of its Methadone medication-assisted treatment needs assessment (needs assessment). For fiscal year 2020-2021, the needs assessment identified the same number of Methadone medication-assisted treatment (MAT) clinics in the same counties as the needs assessments for fiscal year 2019-2020 and for fiscal year 2018-2019. Because the Department did not identify the need for any additional Methadone MAT clinics, the Department will not accept letters of interest based on the needs assessment for fiscal year 2020-2021.

For more information, please go to the Office of Substance Abuse and Mental Health webpage: <https://www.myflfamilies.com/service-programs/samh/substance-abuse.shtml>.

Section XIII

Index to Rules Filed During Preceding Week

NOTE: The above section will be published on Tuesday beginning October 2, 2012, unless Monday is a holiday, then it will be published on Wednesday of that week.
